AlphAIalphai — Financial news for AI agents
marketscreener.comAUG 211 min read

Arbutus Biopharma Corporation authorizes a Buyback Plan.

Arbutus Biopharma's board authorized a share buyback plan on August 21, 2026. The company's stock has seen a 5-day change of $5.210, with a 9.22% increase over the past year.

Original reporting
marketscreener.com
Published Aug 21, 2026, 4:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 22, 2026, 3:03 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefCorporate actions
Primary signal
MARKET
Neutral
AI market analysis
Mentioned
$ABUS
Relevance
4/10
alphai data visualization · based on marketscreener.com
Decision brief

The 30-second read

Low
01

Why it matters

The announcement provides a fresh corporate action that could modestly support the stock price, though the lack of disclosed size limits its materiality.

02

Market read

A new buyback plan is a corporate action that may attract short‑term buying interest.

03

What to watch

No disclosed amount or timeline; market may already price in the news.

Relevance 4/10Novelty 3/10Timing: today

Background

Arbutus Biopharma (NASDAQ: ARBT) announced a board‑approved equity buyback plan.

Market effects

Sector

May signal confidence in biotech sector buyback trends.

Regional

Limited to US biotech investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Buyback size unknown; could be a modest signal without material effect.

Key entities

  • company
    Arbutus Biopharma Corporation

    Biopharma company listed on NASDAQ.

Read at source← All news

Related articles

AUG 24
$ABUSHighAI 8/10

ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week

Arbutus Biopharma (ABUS) shares rose 6% as Moderna (MRNA) is set to make a $950M upfront payment by July 8 under a $2.25B settlement, with ABUS receiving ~$179M. The dispute involved patented lipid nanoparticle technology used in Moderna's COVID-19 vaccine. ABUS also progresses its hepatitis B drug, imdusiran, with FDA Fast Track designation. Analysts rate ABUS a 'buy' with a $5.14 avg. price target.

stocktwits.com2 min
AUG 24
$ABUSHighAI 8/10

Arbutus Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share

Arbutus Biopharma (Nasdaq: ABUS) launched a US$230 million modified Dutch Auction tender offer for up to 23.2% of its shares at US$5.00–US$5.75 per share. The offer, starting August 24, 2026, expires September 29, 2026, unless extended. The company obtained exemptive relief from U.S. and Canadian regulators. The purchase price will be determined based on the tendered shares and prices.

montrealgazette.com2 min
AUG 23
$ABUSHighAI 8/10

ABUS Jumps As Arbutus Biopharma Launches $230M Tender Offer

Arbutus Biopharma (ABUS) stock rose 10.86% after launching a $230M tender offer. The company reported Q2 revenue of $1.0M, negative EBIT, and strong balance sheet metrics, including zero net debt and $271M working capital. Analysts note bullish technical trends and a target range of $6.00–$7.00 over 6–12 months.

timothysykes.com2 min
AUG 21
$ABUSHigh

Why Is Arbutus Biopharma Stock Gaining Friday?

Arbutus Biopharma (ABUS) announced a $230M stock repurchase plan via a modified Dutch auction, offering $5-$5.75 per share. The buyback, funded by cash on hand, follows a $178M settlement with Moderna. The tender offer starts Aug. 24. ABUS shares rose 6.92% to $5.09 Friday. The company is also involved in patent litigation with Pfizer and BioNTech, and developing treatments for hepatitis B.

tradingview.com2 min
AUG 21
$ABUSHighAI 8/10

ABUS Stock Pops As Moderna Settlement Transforms Balance Sheet

Arbutus Biopharma (ABUS) stock rose 7.13% on optimism about its hepatitis B pipeline and a $950M settlement with Moderna, which provided $178M in cash. The company has $92.6M in cash and minimal debt, plans a $230M share buyback, and received FDA Fast Track designation for its RNAi therapy imdusiran (AB-729). Q2 2026 revenue was $1.0M with a net loss of $5.1M.

stockstotrade.com3 min